EMEA Search Results

Newsroom

CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

• CHMP recommendation follows positive Phase 3 study results, marking the second Phase 3 study to demonstrate benefit with a TECVAYLI®-based regimen in the second-line setting1,2 • Results demonstrated significantly improved progression-free and overall survival versus standard of care, reinforcing TECVAYLI®’s potential for patients with relapsed/refractory multiple myeloma (RRMM)1

Newsroom

Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET1 Median overall survival reached 34.3 months with the amivantamab-based regimen, the longest reported to date in this patient population1,2

When Europe Treats Healthcare Innovation as a Cost, Patients Pay the Price

Europe is running out of easy savings. Budgets are tight. Populations are ageing. Yet, too often, the response is the same: cut costs first and weigh the consequences later. Patients, health systems and economies ultimately bear the burden.

Transparency and Targeting of Political Adverting Notice.

Johnson & Johson Article: When Europe Treats Healthcare Innovation as a Cost, Patients Pay the Price. By Christoph Glaetzer

Newsroom

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care

Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1 This immunotherapy doublet regimen demonstrated durable disease control as early as second line, with more than 90% of patients who were progression-free at six months remaining progression-free at three years1

Europe treats new medicines as a cost. The evidence says they’re an investment. 

Europe treats new medicines as a cost.

By Bruno Costa Gabriel. Transparency Notice

Transparency and Targeting of Political Adverting

EU Biotech Act Video Transparency Notice

Newsroom

Johnson & Johnson presents new IMAAVY®▼(nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

• New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infections • To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with nipocalimab • Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalised myasthenia gravis (gMG)

Newsroom

CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

· Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus standard of care1 · Pending approval, this novel complementary immunotherapy combination is positioned to delay disease progression for patients treated as early as second line, with 83% of patients alive at three years1

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

Search Results

No Results

EMEA Search Results